BOLD (Boundless Bio) Total Liabilities: $54.59 Mil (As of Mar. 2026)


BOLD Boundless Bio Inc BOLD
14 GF Score
Price $2.54
! 3 Warning Signs
View Full Analysis

What is Boundless Bio Total Liabilities?

Boundless Bio BOLD +1.99% 14 Total Liabilities is $54.59 Mil as of Mar. 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Boundless Bio's Total Liabilities for the quarter that ended in Mar. 2026 was $54.59 Mil.

Boundless Bio's quarterly Total Liabilities declined from Sep. 2025 ($58.55 Mil) to Dec. 2025 ($58.41 Mil) and declined from Dec. 2025 ($58.41 Mil) to Mar. 2026 ($54.59 Mil).

Boundless Bio's annual Total Liabilities declined from Dec. 2023 ($256.98 Mil) to Dec. 2024 ($55.77 Mil) but then increased from Dec. 2024 ($55.77 Mil) to Dec. 2025 ($58.41 Mil).

Boundless Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Boundless Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio Total Liabilities Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
151.91 158.53 256.98 55.77 58.41

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.65 56.76 58.55 58.41 54.59
BOLD
14GF Score
Boundless Bio Inc BOLD
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boundless Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Boundless Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.537+(45.868+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=58.41

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=157.059-98.654
=58.41

Boundless Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.583+(45.004+7.105427357601E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=54.59

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=140.97-86.383
=54.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $54.59 Mil mean?
Boundless Bio (BOLD) has a Total Liabilities of $54.59 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Boundless Bio and its competitors.
Is Boundless Bio's Total Liabilities too high?
Boundless Bio's current Total Liabilities is $54.59 Mil. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Total Liabilities compare to PLRZ and TVRD?
Boundless Bio's Total Liabilities of $54.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Boundless Bio and its competitors. Boundless Bio's current Total Liabilities is $54.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Total Liabilities of $54.59 Mil. The current Total Liabilities is $54.59 Mil. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Total Liabilities is $54.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Boundless Bio Business Description

Address 10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score

Get the complete analysis for BOLD

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.54
Price